4D Molecular Therapeutics' (FDMT) Sell (E+) Rating Reiterated at Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (e+)" rating restated by stock analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

Other equities research analysts also recently issued research reports about the company. Leerink Partners cut their price target on 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating for the company in a report on Monday, January 13th. Chardan Capital cut their price objective on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Morgan Stanley decreased their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating on the stock in a report on Monday, January 13th. Royal Bank of Canada dropped their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. Finally, Bank of America lowered their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a report on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $30.63.

Remove Ads

4D Molecular Therapeutics Trading Down 1.4 %

Shares of 4D Molecular Therapeutics stock traded down $0.05 on Friday, reaching $3.56. 603,406 shares of the company were exchanged, compared to its average volume of 797,607. The company has a market capitalization of $164.84 million, a price-to-earnings ratio of -1.25 and a beta of 2.83. 4D Molecular Therapeutics has a one year low of $3.50 and a one year high of $36.25. The company has a 50-day moving average of $4.62 and a 200 day moving average of $7.20.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.10). Analysts predict that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in FDMT. KLP Kapitalforvaltning AS acquired a new position in 4D Molecular Therapeutics during the 4th quarter worth approximately $48,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in 4D Molecular Therapeutics in the 4th quarter valued at $50,000. PNC Financial Services Group Inc. increased its stake in 4D Molecular Therapeutics by 66.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock valued at $51,000 after purchasing an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in 4D Molecular Therapeutics by 5,291.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock worth $55,000 after buying an additional 9,737 shares during the last quarter. Finally, Velan Capital Investment Management LP bought a new position in shares of 4D Molecular Therapeutics in the fourth quarter valued at $56,000. Institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.